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Abstract
 
The firm adhesion and transplatelet migration of leukocytes on vascular thrombus are dependent
on the interaction of the leukocyte integrin Mac-1 (
 
 
 
M
 
 
 
2
 
, CD11b/CD18) and the platelet
counter receptor glycoprotein (GP) Ib
 
 
 
. Previous studies have established a central role for the
I domain, a stretch of 
 
 
 
200 amino acids within the 
 
 
 
M 
 
subunit, in the binding of GP Ib
 
 
 
. This
study was undertaken to establish the molecular basis of GP Ib
 
  
 
recognition by 
 
 
 
M
 
 
 
2
 
. The
 
P
 
201
 
–K
 
217 
 
sequence, which spans an exposed loop and amphipathic 
 
 
 
4 helix in the three-
dimensional structure of the 
 
 
 
M
 
I domain, was identified as the binding site for GP Ib
 
 
 
. Mutant
cell lines in which the 
 
 
 
M
 
I domain segments P
 
201
 
–G
 
207
 
 and R
 
208
 
–K
 
217 
 
were switched to the
homologous, but non-GP Ib
 
  
 
binding, 
 
 
 
L 
 
domain segments failed to support adhesion to GP
Ib
 
 
 
. Mutation of amino acid residues within P
 
201
 
–K
 
217
 
, H
 
210
 
–A
 
212
 
, T
 
213
 
–I
 
215
 
, and R
 
216
 
–K
 
217
 
resulted in the loss of the binding function of the recombinant 
 
 
 
M
 
I domains to GP Ib
 
 
 
. Synthetic
peptides duplicating the P
 
201
 
–K
 
217
 
, but not scrambled versions, directly bound GP Ib
 
  
 
and
inhibited 
 
 
 
M
 
 
 
2
 
-dependent adhesion to GP Ib
 
  
 
and adherent platelets. Finally, grafting critical
amino acids within the P
 
201
 
–K
 
217 
 
sequence onto 
 
 
 
L
 
, converted 
 
 
 
L
 
 
 
2 
 
into a GP Ib
 
  
 
binding
integrin. Thus, the P
 
201
 
–K
 
217 
 
sequence within the 
 
 
 
M
 
I domain is necessary and sufficient for
GP Ib
 
  
 
binding. These observations provide a molecular target for disrupting leukocyte–platelet
complexes that promote vascular inflammation in thrombosis, atherosclerosis, and angioplasty-
related restenosis.
Key words: inﬂammation • leukocytes • platelets • adhesion • receptors
 
Introduction
 
Adhesive interactions between vascular cells play important
roles in orchestrating the inflammatory response. Recruitment
of circulating leukocytes to vascular endothelium requires
multistep adhesive and signaling events, including selectin-
mediated attachment and rolling, leukocyte activation, and
integrin-mediated firm adhesion and diapedesis that result
in the infiltration of inflammatory cells into the blood vessel
wall (1). Firm attachment is mediated by members of the
 
 
 
2 
 
integrin family, LFA-1 (
 
 
 
L
 
 
 
 
 
2
 
, CD11a/CD18), Mac-1
 
(
 
 
 
M
 
 
 
2
 
, CD11b/CD18), and p150,95 (
 
 
 
M
 
 
 
2
 
, CD11c/CD18),
which bind to endothelial counter ligands (e.g., intercellular
adhesion molecule [ICAM]-1; 2), endothelial-associated
extracellular matrix proteins (e.g., fibrinogen; 3), or gly-
cosaminoglycans (4).
Leukocyte recruitment and infiltration also occur at sites
of vascular injury where the lining endothelial cells have
been denuded and platelets and fibrin have been deposited.
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Abbreviations used in this paper:
 
 BCECF AM, 2
 
 
 
,7
 
 
 
-bis-(2-carboxyethyl)-5-
(and-6)-carboxyfluorescein, acetoxymethyl ester; GP, glycoprotein; GST,
glutathione 
 
S
 
-transferase; ICAM, intercellular adhesion molecule; MFI,
mean fluorescence intensity; NIF, neutrophil inhibitory factor; RU,
resonance unit; sGP Ib
 
 
 
, soluble extracellular region of GP Ib
 
  
 
(i.e.,
glycocalicin); vWf, von Willebrand factor.T
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A similar sequential adhesion model of leukocyte attach-
ment to and transmigration across surface-adherent platelets
has been proposed (5). The initial tethering and rolling of
leukocytes on platelet P-selectin (6) are followed by their
firm adhesion and transplatelet migration, processes that are
dependent on 
 
 
 
M
 
 
 
2 
 
(5).
Our laboratory has focused on identifying the platelet
counter receptor for 
 
 
 
M
 
 
 
2
 
. Evaluation of the structural fea-
tures of integrins provides insight into candidate platelet
counter receptors for 
 
 
 
M
 
 
 
2
 
. Integrins are heterodimeric
proteins composed of one 
 
  
 
and one 
 
  
 
subunit. A subset of
integrin 
 
  
 
subunits, including 
 
 
 
M
 
, contains an inserted do-
main (I domain) of 
 
 
 
200 amino acids that is implicated in
ligand binding (7–9) and strikingly similar to the A domains
of von Willebrand factor (vWf; 10), one of which, A1, me-
diates the interaction of vWf with its platelet receptor, the
glycoprotein (GP) Ib-IX-V complex. Because of the simi-
larity of the vWf A1 domain and the 
 
 
 
M
 
I domain, we hy-
pothesized that GP Ib
 
  
 
might also be able to bind 
 
 
 
M
 
 
 
2
 
and reported that GP Ib
 
  
 
is indeed a constitutively ex-
pressed counter receptor for 
 
 
 
M
 
 
 
2 
 
(11). Furthermore, un-
der the conditions used in these studies, the predominant
interaction between neutrophils and platelets appeared to
be between 
 
 
 
M
 
 
 
2 
 
and GP Ib
 
  
 
(11).
The 
 
 
 
M
 
I domain contributes broadly to the recognition
of ligands by 
 
 
 
M
 
 
 
2 
 
(12) and specifically to the binding of GP
Ib
 
  
 
(11). This region has been implicated in the binding of
ICAM-1 (13), iC3b (14), fibrinogen (12, 13), and neutro-
phil inhibitory factor (NIF; 15), as well as GP Ib
 
 
 
. Previous
studies suggested that overlapping, but not identical, sites are
involved in the recognition of iC3b, fibrinogen, and NIF
(16, 17). Although the binding sites for iC3b, NIF, and fi-
brinogen in the 
 
 
 
M
 
I domain have been mapped extensively
(18–23), the recognition site for GP Ib
 
  
 
is unknown.
In this study, we have localized the binding site for GP
Ib
 
  within the  MI domain. The strategy developed was
based on the differences in the binding of GP Ib  to the
 MI and  LI domains and involved several independent ap-
proaches, including screening of mutant cells, synthetic
peptides, site-directed mutagenesis, and gain in function
analyses. The binding site for GP Ib  was localized within
the segment  M(P201–K217). The grafting of two amino ac-
ids within this segment into the  LI domain converted it to
a GP Ib –binding protein. Thus, a small segment that has a
defined structure within the  MI domain is necessary and
sufficient for GP Ib  binding.
Materials and Methods
Materials. The soluble extracellular region of GP Ib  (sGP
Ib ; i.e., glycocalicin) was purified as we previously reported
(11). Human fibrinogen depleted of plasminogen, vWf, and fi-
bronectin was purchased from Enzyme Research Laboratories.
The CD11/CD18 mAbs used included the following: LPM19c,
directed to the  MI domain (provided by K. Pulford, Radcliffe,
Oxford, United Kingdom; 12); OKM1, directed to the  M
subunit of human Mac-1 (American Type Culture Collection
[ATCC]); M1/70, directed to the  M  subunit mouse  M 2
(ATCC; 24); CBRM1/5, an activation-specific  M reporter anti-
body (provided by T. Springer, Harvard Medical School, Boston,
MA; 25); TS1/22, directed to the  L subunit of  L 2 and capable
of blocking ICAM-1 binding (ATCC); MEM-83, an activation-
specific  L reporter antibody (Caltag); and IB4, a blocking mAb
directed to the  2 subunit (ATCC). The stimulating CD18 mAb
KIM127 (26) was provided by M. Robinson (Celltech Ltd.,
Slough, United Kingdom). mAb24, a  2 activation reporter anti-
body (27), was provided by N. Hogg (Imperial Cancer Research
Fund, Lincoln’s Inn Fields, London, United Kingdom).
Peptides were obtained from the W.M. Keck Biotechnology
Resource Center at Yale University. The peptides were diluted
in DMSO and stored at  80 C.
Cell Lines and Culture Conditions. THP-1 monocytic cells
(ATCC) were maintained and differentiated with 1 ng/ml TGF-
 1 and 50 nM 1,25-(OH)2 vitamin D3, as previously described
(28). 293 cells expressing human  L 2,  M 2, or mutant  M 2 re-
ceptors were established and maintained as previously described
(16, 20, 23, 29).
Segment Switches by Site-directed Mutagenesis. To systemati-
cally define the GP Ib –binding site in  M, a homologue-scan-
ning mutagenesis strategy was implemented (20). Accordingly,
guided by the crystal structure (8, 9), the hydrated surface of the
 MI domain was replaced with sequences of the  LI domain in
segments of 7–11 amino acids. To apply this approach to the  MI
domain ( 200 amino acids), 16 segments were switched (20, 23).
Site-directed mutagenesis of the  MI domain was performed us-
ing QuikChange Site-Directed Mutagenesis Kit (Stratagene). The
mutations introduced and the mutagenic primers used have been
reported (23). The appropriate DNA sequence of the entire I do-
main (from I139 to A332) was confirmed for each mutant before
transferring back into the  M subunit cDNA.
Transient Transfection. The expression vector pcDNA3.1 (In-
vitrogen) was used for cloning  M,  L, and  2 from human leuko-
cyte cDNA library. 293 cells were transfected using the Lipo-
fectamine 2000 reagent (Invitrogen) with 24  g DNA/vessel for
4 h, according to the manufacturer’s instructions. After transfec-
tion, the medium was replaced with full growth medium. The
functional assays were prepared 48 h after transfection.
Flow Cytometry. FACS® analyses were performed to assess the
expression of wild-type and mutated forms of  M 2 and  L 2 on
the surface of transfected 293 cells, as previously described (11).
Platelet P-selectin expression was assessed using FITC-conjugated
AK-4 or isotype control (BD Biosciences).
Preparation of Neutrophils and Platelets. Neutrophils from wild-
type (Mac-1 / ) and Mac-1–deficient (Mac-1 / ; 30) C57Bl/J6
mice were harvested and purified from the peritoneal cavity after
the intraperitoneal injection of 1 ml sterile 3% thioglycollate
broth, as previously described (11).
Venous blood was obtained from volunteers who had not con-
sumed aspirin or other nonsteroidal antiinflammatory drugs for at
least 10 d and was anticoagulated with 13 mM trisodium citrate,
which also contained 100 nM prostaglandin E1. Platelet-rich
plasma was prepared by centrifugation at 150 g for 10 min. Gel-
filtered platelets were obtained by passage of platelet-rich plasma
over a Sepharose-2B column in calcium-free Tyrode’s-Hepes
buffer containing 100 nM prostaglandin E1, as previously de-
scribed (11).
Adhesion Assays. Adherent cells were assayed by loading
293 cells and thioglycollate-elicited murine neutrophils with 1
 M 2 ,7 -bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, ac-
etoxymethyl ester (BCECF AM), according to the manufacturer’s
instructions (Molecular Probes). 105 cells/well were placed in 96-T
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well microtiter plates coated with 10  g/ml sGP Ib  or 10  g/
ml fibrinogen and blocked with 0.2% gelatin. Adhesion was stim-
ulated with 20 ng/ml PMA or 5  g/ml of the  2-stimulating
mAb KIM 127. Plates were washed and adhesion was quantified
by measuring the fluorescence of BCECF AM–loaded cells using
a Cytofluor II fluorescence microplate reader (PerSeptive Biosys-
tems). The effect of anti- M mAb on adhesion was assessed by
preincubating cells with 10  g/ml LPM19c. The effect of pep-
tides M1–M8 on adhesion was investigated by incubating the in-
dicated peptide with sGP Ib –coated wells for 30 min at 37 C
before the addition of cells. Data are expressed as percent adhe-
sion of control treatment.
Neutrophil Adhesion to Surface-adherent Platelets. Neutrophil
adhesion to surface-adherent platelets was investigated as previ-
ously described (11). The effect of  M peptides on leukocyte adhe-
sion to platelets was examined by preincubating surface-adherent
platelets with peptide (1–1,000 nM) or vehicle for 30 min at 37 C.
Data are expressed as percent adhesion of control treatment.
Site-directed Mutagenesis, Expression, and Purification of I Domain
Fusion Proteins. The cDNAs of  MI domain (675 nucleotides,
R115–S340),  LI domain (630 nucleotides, P120–S330), and mouse
 MI domain (675 nucleotides, L115–S340) were cloned and inserted
into the pGEX-5X-3 expression vector (22). All wild-type and
mutant I domains were expressed as glutathione S-transferase
(GST) fusion proteins. Mutations were created in these I domains
and intact  L by oligonucleotide-directed mutagenesis. The selec-
tive introduction of the desired mutations into the I domains was
confirmed by DNA sequence analyses. The GST-I domain fusion
proteins were purified by adsorption onto glutathione-Sepharose
4B (Amersham Biosciences) and eluted with buffer containing 50
mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM glutathione, 2.5
mM CaCl2. Such preparations of the fusion proteins were  90%
pure as assessed by SDS-PAGE.
GP Ib  Binding to the I Domains. To test the interaction of
the wild-type  M,  L, and chimeric I domains with biotinylated
GP Ib , 96-well plates (Immulon 4BX; Dynex Technologies
Inc.) were coated with the I domains at 50  g/ml and blocked
with 2% BSA. sGP Ib  in 20 mM Tris-HCl, pH 7.6, containing
100 mM NaCl and 2 mM CaCl2, was added to the wells and in-
cubated for 1 h at 37 C. After washing, bound GP Ib  was de-
tected using avidin-alkaline phosphatase and p-nitrophenyl phos-
phate. Background reaction on BSA-coated wells was subtracted.
BIAcore Surface Plasmon Resonance Analysis. Real-time pro-
tein–protein interactions were examined using surface plasmon
resonance on a BIAcore 1000 (BIAcore AB). Immobilization of
peptides was performed via thiol coupling onto a sensor chip C1
using 20 mM Tris, 150 mM NaCl, 2 mM MgCl2, pH 7.4, as run-
ning buffer at a flow rate of 5  l min 1. Modified versions of pep-
tides containing an amino-terminal cysteine residue were synthe-
sized and then diluted in10 nM acetate buffer, pH 5.0 (coupling
buffer). The peptide was loaded on the chip for 16 min and immo-
bilization occurred via thiol disulfide exchange. Identical treatment
was applied to the reference flow cell without peptide (control sur-
face). For analysis, sGP Ib  diluted into running buffer was in-
jected at a flow rate of 10  l/min. Binding (resonance unit [RU])
was measured as a function of time(s). Binding data (after subtract-
ing nonspecific background binding to the control surface) are pre-
sented as sensorgrams, binding curves, and Scatchard plots (31).
In Vitro Analysis of Cellular Adhesion under Laminar Flow Condi-
tions. The laminar flow chamber used in this assay has been de-
scribed (32). 25 mm2 diameter glass coverslips (Assistent; Carolina
Biological Supply Company) were coated with a solution of 20
 g/ml soluble P-selectin (provided by R. Camphausen, Genetics
Institute, Cambridge, MA) and 40  g/ml sGP Ib  for 2 h at
room temperature. Nonspecific interactions were blocked with
PBS containing 1% human serum albumin for 1 h at room tem-
perature and with 0.1% Tween 20 immediately before use. The
effect of M2 and scM2 peptides on THP-1 cell rolling and firm
arrest was examined by incubating 50  M of the peptide with the
ligand-coated glass coverslip for 1 h at room temperature. To
block PSGL-1 and  M 2 interactions, THP-1 cells were incu-
bated with 20  g/ml KPL-1 (BD Biosciences) or 20  g/ml
LPM19c mAb, respectively, for 20 min before perfusion.  M 2
was activated by treating cells with 10  g/ml KIM127 for 5 min
before perfusion. The rolling and firm adhesive events scored
were ligand specific as confirmed in parallel determinations on
control substrates coated with human serum albumin. Coverslips
were inserted in the flow chamber and 0.6   106/ml THP-1 cells
were drawn across at an estimated shear stress of 0.75 dynes/cm2
using a syringe pump (Harvard Apparatus). After 3 min of perfu-
sion, the number of rolling and arrested cells was quantified in
each of five random 10x fields (area  0.3 mm2) by an investigator
blinded to treatment.
Statistics. Data are presented as the mean    SD or SEM.
Groups were compared using the nonpaired t test. Rolling and
arrest data were analyzed using repeated measure ANOVA with a
Bonferroni corrective for multiple comparisons. P values  0.05
were considered significant.
Results
Binding of GP Ib  to Mutant Cell Lines. Our previous
report indicated that the  MI domain serves as a recognition
site for GP Ib  (11). The adhesion of  M 2-bearing cells to
sGP Ib  was inhibited by LPM19c, an mAb that binds to
the  MI domain. To establish definitively that the  MI do-
main serves as a recognition site for GP Ib , we transfected
293 cells with wild-type  M 2,  L 2, or a chimeric  L 2
receptor that contained the I domain of  M 2  (i.e.,
 L(I M) 2-transfected 293 cells).  L 2-transfected 293 cells
did not adhere to sGP Ib . In contrast,  L(I M) 2-trans-
fected 293 cells adhered robustly to sGP Ib  in a manner
similar to  M 2-transfected 293 cells, indicating that the  MI
domain is required for adhesion to sGP Ib . These data sug-
gest that although  M 2 and  L 2 are highly homologous
integrins, the lack of binding of sGP Ib  to  L 2 might be
the result of sequence and/or structural differences.
As the first step to define the binding site for GP Ib 
within the  MI domain, mutant cell lines, each expressing a
mutant  M 2 in which a short  MI domain sequence, cor-
responding to a structural unit in the crystal structure (8, 9),
was replaced for the corresponding region of the  LI do-
main, were tested for their adhesion to immobilized sGP
Ib . 16 segments were switched from their original  MI
domain to their counterparts in  L (16, 20, 23). These seg-
ment swaps are placed throughout the P147–Q314 region of
the  MI domain, D132–A318, and are intended to cover its
entire hydrated surface (8, 9). For such experiments to be
readily interpretable, cell lines expressing high and similar
levels of wild-type and mutant receptors were selected by
cell sorting using mAbs OKM1 and IB4 followed by clon-
ing by limiting dilution. The expression of the receptors
as assessed by the mean fluorescence intensity (MFI) inT
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FACS® analyses differed by less than twofold from the in-
ternal wild-type control (not depicted).
The results of adhesion of 16 mutants to sGP Ib  are
summarized in Fig. 1. The data are expressed as the percent
adhesion of the wild-type  M 2-expressing cells to sGP
Ib . Substitutions for the following regions of  MI domain
abrogated adhesion:  M(P147–R152),  M(M153–T159),  M(E162–
L170),   M(P201–G207),   M(R208–K217),   M(K245FG247),   M
( D248–Y252),   M(E253–R261),   M(D273–K279),   M(R281–
I287), and  M(F297–T307). These cell lines form a group of
negative mutants. As the essential control, the  L 2-
expressing cells adhered poorly to sGP Ib , consistent with
lack of interaction of  L 2 with sGP Ib .
The lack of adhesion of these mutants was not the result
of decreased surface expression of the receptor because there
was no correlation between the level of adhesion and ex-
pression. Specifically, surface expression of the  M(P201–
G207) mutant was 1.5-fold higher than that of the cells
expressing the wild-type  M 2 cells, but adhesion was
abrogated completely. Surface expression of negative
mutants,  M(P147–R152),  M(R208–K217),  M(E253–R261), and
 M(D273–K279) was very similar to that of the wild-type re-
ceptor. Adhesion of  M(E178–T185) and  E262G263 was par-
tially affected. The maximal level of adhesion to sGP Ib 
reached 69 and 64%, respectively, of wild-type  M 2 cells.
These two receptors were classified as intermediate mutants.
The following mutants supported the same or higher
levels of adhesion to sGP Ib  compared with the cells ex-
pressing the wild-type  M 2  receptor:   M(Q190–S197),
 M(K231NAF234),   M(E262–G263), and  M(Q309–E314). The
cell lines exhibiting adhesion similar to or greater than
the wild-type  M 2 cells were identified as positive mu-
tants. Two of these positive mutants,  M(Q190–S197) and
 M(K231NAF234), bound sGP Ib   better than wild-type
 M 2. Previous analyses using these mutants showed that
they bound neither an  M 2 activation-independent ligand,
NIF (20), nor  M 2 activation-dependent ligands, C3bi
(17) and fibrinogen (23), to a greater extent than wild-type
receptor. Thus, the enhanced binding of these mutants ap-
pears to be selective for sGP Ib  recognition. In further
studies, we found that binding of the  2 activation–specific
reporter mAb 24 was similar for wild-type and the  M
(Q190–S197) and  M(K231NAF234) mutants. In contrast,
increased binding of the  M activation–specific reporter
CBRM1/5 to  M(K231NAF234) compared with wild-type
 M 2  and   M(Q190–S197) suggests possible conformation
change of the  M(K231NAF234) mutant (not depicted). To-
gether, these observations suggest that the activation states
of  M 2 may reflect the reporter ligand or mAb used, and
these two mutants might be functionally activated with re-
spect to sGP Ib  recognition.
Interaction of GP Ib  with the  MI Domain Peptides. In
subsequent analyses, we focused on the 11 negative mu-
tants. A series of peptides (M1–M8) corresponding to the
wild-type   MI domain sequences were synthesized and
tested for their ability to interact with sGP Ib . Because the
sequences within several of the negative mutants were con-
tiguous, the following linear peptides spanning these se-
quences were synthesized: P147–T159 (designated M1), P201–
K217 (M2), K245–R261 (M3), D273–I287 (M4), F297–T307 (M5),
Q190–S197 (M6), E162–L170 (M7), and E178–T185 (M8). All
peptides correspond to negative mutant sequences except
M6 and M8, which correspond to intermediate and posi-
tive mutant sequences, respectively.
Next, we examined the effect of these  MI domain pep-
tides on  M 2-dependent adhesion to sGP Ib  or fibrino-
gen (Table I). 50  M peptides were preincubated in
ligand-coated wells,  M 2-expressing 293 cells were added,
and adhesion was stimulated with KIM 127. Mac-1 293
cells adhered to sGP Ib  and fibrinogen, and this adhesion
was blocked by the anti-CD11b mAb LPM19c, indicating
that adhesion is predominantly  M 2 dependent (Table I).
Peptide M2 inhibited adhesion to sGP Ib  (percent inhibi-
tion   74   13; P   0.01). Interestingly, M2 had no effect
on cellular adhesion to fibrinogen. All other peptides had
minimal or no effect on  M 2-expressing 293 cell adhesion
to sGP Ib  or fibrinogen. M2, but not a scrambled version
(scM2), blocked  M 2-dependent adhesion to sGP Ib  in a
dose-dependent manner (IC50   20  M; Fig. 2). Taken to-
gether, these observations suggest that the  MI domain se-
Figure 1. Binding of GP Ib  to mutant cell lines.
Adhesion of 105  M 2-,  L 2-, and mutant  M 2-
expressing 293 cells to sGP Ib –coated wells. Adhe-
sion was promoted by the addition of 5  g/ml of the
stimulating mAb KIM 127 and quantified by measuring
the fluorescence of BCECF AM–loaded cells. Data are
expressed as percent wild-type  M 2 adhesion (mean  
SD of three to five independent experiments). A series
of peptides (M1–M8) corresponding to the wild-type
 MI domain sequences were synthesized and tested for
their ability to interact with sGP Ib  (Table I). Because
the sequences within several of the negative mutants
were contiguous, linear peptides spanning these sequences
were synthesized: P147–T159  (M1), P201–K217  (M2),
K245–R261 (M3), D273–I287 (M4), F297–T307 (M5), Q190–
S197 (M6), E162–L170 (M7), and E178–T185 (M8). All pep-
tides correspond to negative mutant sequences except
M6 and M8, which correspond to intermediate and
positive mutant sequences, respectively.T
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quence corresponding to M2 (P201–K217), which spans an
exposed loop and amphipathic  4 helix in the three-
dimensional structure of the  MI domain, contributes to
 M 2 binding of GP Ib .
Real-Time Detection of Protein–Protein Interaction by BIAcore
Analyses Reveals Specific, Direct Binding of GP Ib  to M2 Pep-
tide. To examine direct interactions between GP Ib  and
M2, we used an in vitro real-time binding assay using surface
plasmon resonance (BIAcore). M2 and scM2 peptides were
modified by addition of an amino-terminal cysteine and im-
mobilized via thiol coupling on a C1 sensor chip. Cys-M2,
but not Cys-scM2, inhibited  M 2-dependent adhesion to
sGP Ib , verifying that cysteine addition did not adversely
affect peptide structure (Table I). Increasing concentrations
of purified sGP Ib  in running buffer containing 2 mM
MgCl2 were injected over the chip surface and the sensor-
grams were recorded. As shown in Fig. 3, the sensorgrams
detected little interaction between sGP Ib  and control chips
or chips containing immobilized scM2. Significant interac-
tion responses were detected for sGP Ib  with M2. Appar-
ent equilibrium dissociation constant was estimated from the
equilibrium resonance signal as a function of analyte (GP
Ib ) concentration (kD  20  M) and calculated by Scat-
chard analysis (kD   17  M). Similar results were obtained
when purified sGP Ib  in running buffer containing 2 mM
CaCl2 were injected over the chip surface (not depicted).
Thus, BIAcore analysis revealed real-time, direct binding for
bimolecular interactions between GP Ib  and M2.
GP Ib  Binding to “Triple Mutants” of the  MI Domain.
To begin localization of specific amino acid residues within
the  MI domain involved in GP Ib  recognition, recombi-
nant fragments containing wild-type  MI domain, R115–
S340, wild-type  LI domain, P120–S330, and a mutant  MI do-
main were expressed as GST fusion proteins in Escherichia
coli. The mutant  MI domain contained a swap of the P201–
K217 segment, which we implicated in sGP Ib  binding to
the corresponding residues of the  LI domain. The recom-
binant proteins were purified from the bacterial lysates on
glutathione-Sepharose. A facile binding assay for quantify-
ing sGP Ib  binding to the recombinant I domains was de-
veloped by measuring the binding of biotinylated sGP Ib 
to the recombinant I domains immobilized onto 96-well
plastic plates. As shown in Fig. 4, GP Ib  exhibited minimal
reaction with  LI domain. Binding was observed and was
similar with both human and mouse  MI domains. With the
 MI domains, binding was dependent on the sGP Ib  con-
Table I. Effect of  MI Domain Peptides on  M 2 293 Cell Adhesion to sGP Ib  and Fibrinogen
Peptide or mAb  MI domain sequence Peptide sequence
Percent  M 2 293
adhesion to sGP Ib 
Percent  M 2 293
adhesion to fibrinogen
M1 P147–T159 PHDFRRMKEFVST 76   18 118   27
M2 P201–K217 PITQLLGRTHTATGIRK 26   13a 102   46
M3 K245–R261 KFGDPLGYEDVIPEADR 94   20 136   32
M4 D273–I287 DAFRSEKSRQELNTI 110   36 115   8
M5 F297–T307 FQVNNFEALKT 96   16 105   12
M6 Q190–S197 QNNPNPRS 93   17 107   3
M7 E162–L170 EQLKKSKTL 79   31 103   3
M8 E178–T185 EEFRIHFT 66   27 104   11
C-M2 P201–K217 CPITQLLGRTHTATGIRK 26   1a ND
scM2 LGTRITHQRTGPTIKL 80   15 ND
LPM19c Anti- MI domain 6.3   5.7b 6.1   6.6b
The adhesion of  M 2-expressing 293 cells to sGP Ib – or fibrinogen-coated microtiter wells was stimulated by the addition of 5  g/ml KIM 127
in the presence and absence of 50  M  MI domain peptides or 10  g/ml antibody (LPM19c). Data are expressed as percent adhesion with vehicle
alone. Mean   SD, n   3–5.
aP   0.01.
bP   0.0001.
Figure 2. Effect of M2 peptide on  M 2-dependent adhesion to GP
Ib . 293 cells expressing  M 2 were added to sGP Ib –coated wells pre-
incubated with 0–50  M M2 ( ) or scM2 ( ) peptides. Adhesion was
promoted by the addition of 5  g/ml of the stimulating mAb KIM 127
and quantified by measuring the fluorescence of BCECF AM–loaded
cells. Data represent mean   SD, n   3 independent experiments.T
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centration with 50% maximal binding observed at 50 nM
sGP Ib , which was used in subsequent experiments. As
shown in Fig. 5 A, the interaction of the  MI domain
“swap” mutant with biotinylated sGP Ib  was greatly di-
minished compared with wild-type  MI domain and similar
to that of the  LI domain. Essentially, no specific binding of
sGP Ib  to this mutant I domain was detected. This result is
consistent with our BIAcore binding experiments showing
a direct interaction between sGP Ib  and immobilized M2
peptide corresponding to this P201–K217 segment.
To begin to identify the individual residues within the
P201–K217 segment that mediated sGP Ib  recognition, a se-
ries of six triple mutants were created. In each of these tri-
ple mutants, a set of three consecutive amino acids within
the  MI domain was changed to the corresponding  L resi-
dues. If the  M and  L residues were the same, the amino
acid was mutated to alanine. After the DNA sequence of
each mutant I domain was confirmed, it was expressed in
E. coli and purified on glutathione-Sepharose. When ana-
lyzed by SDS-PAGE, each mutant migrated as a single
band of  52 kD (not depicted). sGP Ib  binding to each
triple mutant was then assessed. The results in Fig. 5 A
show the binding of each of the six triple mutants to 50 nM
biotinylated sGP Ib . Of the six triple mutants, three,
H210–A212, T213–I215, and R216–K217, showed a significant
reduction in sGP Ib  binding. Three mutants, P201–T203,
Q204–L206, and G207–T209, did not impair binding to GP
Ib . These results, taken in light of the observation that
mutating the entire region spanning P201–G207 abolished
cell adhesion to sGP Ib  (Fig. 1), suggest that the inactiva-
tion of sGP Ib  binding requires alteration of more than
one residue within the P201–G207 (i.e., no single residue
within the triple mutants, P201–T203, Q204–L206, and G207–
T209, decreases affinity detectably), or the conformation of
the P201–G207 segment, which corresponds to a portion of a
loop within the  MI domain, is necessary for binding, and,
again, no single substitution alters the conformation of this
region sufficiently to prevent binding.
GP Ib  Binding to “Single Point Mutants” of the  MI Do-
main. Next, within the three triple mutants with reduced
sGP Ib  binding, each of the three amino acids was mu-
tated individually to the corresponding residue in  LI do-
main or in case of identical residues in two I domains, the
amino acid was replaced with an alanine. After confirming
the DNA sequences of these single mutants, each of the
GST fusion proteins was purified. The mutant fusion pro-
tein carrying the K217Y substitution was insoluble. There-
fore, K217 was mutated to Ala, and this  MI domain with a
K217A substitution was readily purified, yielding a total of
eight single mutants. The capacity of the eight single mu-
tants to bind sGP Ib  is summarized in Fig. 5 B. Within
each of the three triple mutants with reduced sGP Ib  rec-
ognition, only one of the three single mutants exhibited re-
duced sGP Ib  binding. These three single mutants show-
ing reduced binding were T211A, T213G, and R216N.
Development of a Chimeric  LI Domain with GP Ib  Bind-
ing Activity. Loss of GP Ib  binding function in these sin-
gle mutants could reflect direct involvement of the specific
residues in GP Ib  binding or conformational perturbation
of the resulting  MI domain due to substitutions at these
positions. A gain in function approach was used to distin-
guish between these possibilities by introducing the identi-
Figure 3. BIAcore analysis of the interaction between GP Ib  and M2.
(A) 0–100  M sGP Ib  in running buffer injected over control chips
(dashed line) or chips immobilized with Cys-M2 (solid line) or Cys-scM2
(dotted line) for 4 min at a flow rate of 10  l/min followed by running
buffer alone. In all cases, sensograms obtained with control flow cells
were subtracted from those obtained with immobilized peptides. (B) Plot
of RU as a function of GP Ib  concentration. The inset shows Scatchard
analysis to obtain apparent equilibrium dissociation constant (kD   17
 M). RU, resonance unit.
Figure 4. GP Ib  binding to recombinant I domains. Biotinylated sGP
Ib  was added at the indicated concentrations to  MI domain GST fusion
proteins immobilized on microtiter wells. The various I domains are: human
 MI domain ( ), mouse  MI domain ( ), and the  LI domain ( ). Incu-
bations were performed in the presence of 2 mM Ca2 , and samples were
processed as indicated in Materials and Methods. Each dataset is the
mean   SEM of at least three independent experiments.T
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fied point mutations into the  LI domain. T211 is conserved
in both  MI and  LI domains. Therefore, chimeric I do-
mains containing either a single G213T substitution or two
substitutions, G213T and N216R, in the  LI domain back-
bone were created. These mutant  LI domains were ex-
pressed as GST fusion proteins, purified, and their sGP Ib 
binding properties were evaluated. The chimeric I domain
harboring both the G213T and N216R mutations bound sGP
Ib  with an affinity substantially greater than wild-type  LI
domain and the I domain containing the single G213T mu-
tation (Fig. 6). Indeed, the binding capability of double
substituted chimeric I domain was comparable to the
wild-type  MI domain. To confirm that these two amino
acid residues are sufficient to impart sGP Ib  recognition
to the mutated  LI domain, we performed additional BIA-
core binding assays with immobilized  LI domain peptide
(C201HVKHMLLTNTFGAINY217, termed C-L2) corre-
sponding to the P201–K217 sequence within  MI domain and
the double substituted mutant C201HVKHMLLTN-
TFTAIRY217  (C-muL2). Binding assays were also per-
formed with a mutant M2 peptide containing T211A,
T213G, and R216N substitutions (C201PITQLLGRTH-
AAGGINK217, termed C-muM2) corresponding to the
three single mutants showing reduced binding in the puri-
fied mutant I domain binding assays (Fig. 5 B). The sensor-
grams detected little interaction between 50  M sGP Ib 
and chips containing immobilized C-L2 (RU   10) or
C-muM2 (RU    25). Significant interaction responses
were detected for sGP Ib  with C-muL2 (RU   224).
Role of the Identified Amino Acids in the Context of Intact
 M 2. The role of T213 and R216 in the GP Ib  binding
function of the intact receptor was investigated. The T213G
and R216N substitutions were introduced into the cDNA
for the  L subunit using site-directed mutagenesis and coex-
pressed with the cDNA for the  2 subunit in 293 cells.
Wild-type  L 2 and  M 2 were also transiently expressed in
these cells as controls. 48 h after transfection, the cells were
detached from tissue culture plates, and receptor expression
levels were evaluated by FACS®.  M expression was evalu-
ated with OKM1,  2 expression with IB4, and  L expres-
sion with TS1/22. The expression levels of both the   and
  subunits of the integrins were comparable (not depicted).
Next, the function of the receptors was assessed by evaluat-
ing their adhesion to immobilized sGP Ib . PMA, Mn2 , or
their combination were used to activate the integrins on the
cells. As shown in Fig. 7, mock-transfected cells or cells ex-
pressing wild-type  L 2 showed little adhesion to sGP Ib 
under all conditions. When  M 2-expressing cells were
stimulated with PMA, Mn2 , or their combination, their
adhesion to sGP Ib  increased markedly compared with the
nonstimulated cells. The chimeric  L 2 cells adhered to sGP
Ib  considerably better than the  L 2 cells or mock-trans-
fected cells. The adhesion of the chimeric  L 2 cells ap-
proached that of the wild-type  M 2 cells. We considered
whether inserting these amino acid residues into  L might
affect the activation state of chimeric  L 2 such that the in-
crease in binding might reflect allosteric changes in the inte-
Figure 5. GP Ib  binding to  MI domain triple mutants (A) and  MI
domain single mutants (B). The GST fusion proteins were adsorbed onto
wells of microtiter plates, and sGP Ib  binding was measured using a 50-nM
concentration of ligand. Each dataset is the mean   SEM of at least three
independent experiments.
Figure 6. GP Ib  binding to the chimeric  LI domain. Biotinylated
sGP Ib  binding was measured as in Fig. 1 to wild-type  MI domain ( ),
the  LI domain ( ), the chimeric  LI domain ( ) containing the single
G(213)T mutation, and the chimeric  LI domain containing the double
G213T and N216R substitutions ( ). Values are presented as the mean  
SEM of at least three separate experiments.T
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grin. Accordingly, we assessed the activation states of the
chimeric integrin using MEM-83, an mAb that reacts with
activated  L 2 (33). In FACS® analyses, MEM-83 failed to
react with either the  L 2 or the chimeric  L 2 transfectants
in the unstimulated state (MFI   14 and 10, respectively),
but reacted well and equivalently with both transfectants
upon stimulation with the combination of Mn2  and PMA
(MFI   79 and 83, respectively). Thus, the activation states
of both the  L 2 and chimeric  L 2 transfectants, with and
without stimulation, were similar.
 M 2 and GP Ib  Facilitate the Interaction between Leuko-
cytes and Platelets. Having previously reported that  M 2
and GP Ib  facilitate the heterotypic interaction between
leukocytes and platelets, we turned to examining the effect
of M2 on neutrophil adhesion to platelets. Thioglycollate-
elicited neutrophils were added to wells containing surface
adherent platelets and adhesion was stimulated by the addi-
tion of PMA to each well. We verified by FACS® analysis
that such PMA treatment up-regulated P-selectin expres-
sion 29.9-fold in platelets purified and prepared with PGE1
as described in Materials and Methods. Wild-type (Mac-
1 / ) neutrophils bound to adherent platelets (Fig. 8). In
contrast, Mac-1–deficient (Mac-1 / ) neutrophils demon-
strated markedly reduced adhesion to platelets (percent
wild-type adhesion   18.2   8.0) and adhesion of wild-
type neutrophils was blocked by the rat anti–mouse  M 2
mAb M1/70 (percent wild-type adhesion   29.9   19.8),
indicating that under these conditions, neutrophil adhesion
to platelets is largely  M 2 dependent, although a compli-
mentary role for P-selectin/PSGL-1 is likely operative.
M2, but not a scrambled version, inhibited dose depen-
dently (IC50   30 nM) wild-type neutrophil adhesion to
platelets. Taken together, these observations indicate that
under these experimental conditions, neutrophil adhesion
to platelets is mediated primarily by the  MI domain se-
quence P201–K217.
M2 Peptide Abrogates the Firm Adhesion of THP-1 Cells un-
der Flow. To evaluate the potential for M2 to modulate
the adhesion of blood cells under flow, we perfused THP-1
cells that express Mac-1 over coverslips coimmobilized
with soluble P-selectin and GP Ib  using a parallel plate
flow chamber system (0.75 dynes/cm2). The number of
rolling and arrested cells was quantified on five random
fields after 3 min of perfusion. THP-1 cells rolled and ar-
rested on coverslips cocoated with P-selectin and sGP Ib 
and the number of rolling (control vs. scM2, P   0.05) or
arrested (control vs. scM2, P   0.05) cells was unaffected
by scM2 (Fig. 9 A). In contrast, M2 peptide inhibited
THP-1 cell arrest, thereby increasing the number of rolling
cells visualized. The effect of M2 on cell adhesion was sim-
ilar to treatment with LPM19c, an anti-CD11b mAb that
blocks  M 2-dependent binding to sGP Ib , thereby con-
firming the involvement of  M 2 in cell adhesion. Both cell
rolling and arrest were abolished by treating cells with
KPL-1, an anti–PSGL-1 mAb that blocks P-selectin bind-
ing. The effect of M2 on cell arrest was also quantified.
Thus, on coverslips incubated with vehicle or scM2, 64
and 66% of THP-1 cells arrested, respectively (Fig. 9 B).
After treatment with M2 peptide only 34% of cells arrested
(P   0.05). Similarly, after preincubation of THP-1 cells
with LPM19C, only 33% of cells arrested (P   0.05). KPL-1
antibody treatment abrogated almost all rolling and subse-
quent arrest ( 10%; P   0.01).
Discussion
In this study, we have identified the P201–K217 segment,
which spans an exposed loop and amphipathic  4 helix in
the three-dimensional structure of the  MI domain, as the
binding site for platelet GP Ib . This conclusion is sup-
ported by the following data: (a) mutant cell lines in which
the   MI domain segments P201–G207 and R208–K217 were
Figure 7. GP Ib  binding to the chimeric  L 2. Adhesion of mock-
transfected 293 cells (open bars),  L 2-transfected cells (solid bars),  M 2-
transfected cells (gray bars), and cells expressing the chimeric  L 2 receptor
(striped bars) to sGP Ib –coated wells. The percentage of input cells
adherent after washing was calculated. Values are the mean   SEM of
three individual experiments.
Figure 8. Neutrophil binding to platelets is inhibited by M2 peptide.
Neutrophils from wild-type (Mac-1 / ) or Mac-1–deficient (Mac-1 / ,  )
mice were added to surface-adherent platelets. Adhesion was promoted
by the addition of 17 ng/ml PMA. The contribution of  M 2 to wild-
type neutrophil adhesion to platelets was also assayed by the addition of 10
 g/ml rat anti–mouse  M mAb M1/70 ( ). The effect of 0–1,000 nM
M2 ( ) and scM2 ( ) on neutrophil adhesion was also examined. Adhe-
sion was quantified by measuring the fluorescence of BCECF AM–
loaded neutrophils. Data are expressed as percent wild-type neutrophil
adhesion with vehicle alone (mean   SD, n   3 independent experiments).T
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switched to the homologous  LI domain segments failed to
support adhesion to sGP Ib , (b) mutation of amino acid
residues within P201–K217, H210–A212, T213–I215, and R216–
K217 resulted in the loss of the binding function of the re-
combinant  MI domains to biotinylated sGP Ib , (c) syn-
thetic peptides duplicating the P201–K217, but not scrambled
versions, directly bound sGP Ib  and inhibited  M 2-depen-
dent adhesion to sGP Ib  and adherent platelets, and (d)
grafting key amino acids within the P201–K217 sequence onto
 L converted  L 2 into a GP Ib  binding integrin.
By virtue of binding diverse ligands including, among
others, fibrin(ogen) (34, 35), ICAM-1 (36), factor X (37),
C3bi (34), high molecular weight kininogen (38), and
heparin (4),  M 2 regulates important leukocyte functions
including adhesion, migration, coagulation, proteolysis,
phagocytosis, oxidative burst, and signaling (30, 39–42).
However, these ligands do not account for all of  M 2’s ad-
hesive interactions. Although previous studies have shown
that  M 2 directly facilitates the recruitment of leukocytes
at sites of platelet and fibrin deposition (5), the precise
platelet counter receptors, including GP Ib   (11) and
JAM-3 (43), have been elucidated only recently.
In this study, we have identified key elements of the
binding site for GP Ib  within the  MI domain. The strat-
egy to define the ligand binding site was based on the dif-
ference in the sGP Ib  binding properties of the  MI and
 LI domains and entailed four complimentary approaches.
In the first approach, a series of homologue-scanning mu-
tants, used previously to map the binding regions for NIF,
iC3b, and fibrinogen (16, 20, 23), were screened for adhe-
sion to sGP Ib . In these mutants, 16 segments at the hy-
drated surface of the  MI domain were replaced with the
corresponding segments from the homologous  LI domain,
which does not bind GP Ib . 11 mutants lacked the ability
to support adhesion sGP Ib , and alteration of two other
regions,  M(E178–T185) and  M( E262G263), resulted in the
partial loss of adhesive function. Thus, the initial insight
provided by these mutant receptors indicated that the sGP
Ib  binding interface within the  MI domain was com-
posed of several nonlinear sequences.
The second approach entailed the use of synthetic pep-
tides duplicating the sequences of the critical segments in
the  M I domain. These analyses showed that two critical
segments,  M(P201–G207) and  M(R208–K217), may contain
amino acid residues that participate directly in binding GP
Ib  because the peptide M2 that spanned P201–K217 bound
sGP Ib  and inhibited  M 2-dependent adhesion to sGP
Ib  and adherent platelets. The negative results for other
peptides (M1, M3–M5, and M7) synthesized to correspond
to other negative mutants (Fig. 1 and Table I) do not ex-
clude a role for other  MI domain segments in binding
function. These segments may play an accessory role in
ligand binding or the short peptides may simply not assume
the appropriate conformation for recognition by the ligand.
Finally, segments implicated in the binding of sGP Ib  by
the negative mutants, other than P201–K217, may reflect in-
terference by  LI domain residues rather than residues that
actually participate in binding. It is also possible that the ac-
tivation of  M 2, rather than ligand binding per se, was af-
fected adversely by the introduction of these  L segments
within  MI domain. Because these same mutants have been
used in previous studies (17, 20, 23) to analyze interaction
of other activation-dependent ligands with  M 2, such ef-
fects on activation would need to specifically perturb GP
Ib  recognition.
To obtain direct evidence that the  M(P201–K217) se-
quence constitutes the functional binding site for the GP
Ib , we turned to a third approach using site-directed mu-
tagenesis of the  MI domain. Binding experiments with
purified sGP Ib  and GST-I domain mutants provided the
independent confirmation that the P201–K217 segment is im-
portant for sGP Ib  binding because mutations of these
residues resulted in significant loss of sGP Ib   binding.
These experiments also served to narrow further the bind-
ing region to H210–K217 and subsequently identified three
single mutants showing reduced binding to sGP Ib 
(T211A, T213G, and R216N). Of these, T211 in  MI domain is
conserved in the  LI domain. Thus, it was the conversion
of the residue to A that perturbed GP Ib  binding, suggest-
ing that this substitution exerts a negative influence on the
conformation of the  MI domain that is required for GP
Ib  recognition, rather than participating directly in ligand
contact. The positioning of this residue on the interior of
the  4-helix and facing the central core of the  MI domain,
according to the crystal structures (8, 9), supports this inter-
pretation. In contrast, T213 and R216 are appropriately posi-
tioned, including when the recent crystal structure of the
GP Ib /vWF A domain (44) is used as a template.
In the fourth approach, the two amino acids (T213G and
R216N substitutions) within the  M(P201–K217) were grafted
Figure 9. THP-1 cell adhesion under flow is in-
hibited by M2 peptide. Soluble GP Ib  was coim-
mobilized with P-selectin on coverslips. 0.6   106/ml
THP-1 cells were activated with KIM 127 and drawn
across the substrates at 0.75 dynes/cm2 as detailed in
Materials and Methods. The effect of M2 and scM2
peptides on THP-1 cell rolling and firm arrest was
examined by preincubating 50  M of the peptide
with the ligand-coated coverslip. To block PSGL-1
and  M 2 interactions, THP-1 cells were incubated
with 20  g/ml KPL-1 or LPM19c mAb, respectively,
for 20 min before perfusion. The absolute number of rolling and arrested cells was quantified per  10 field on five random fields after 3 min of perfusion.
Data represent the mean   SEM, n   3 independent experiments. *, P   0.05 versus control peptide; **, P   0.01 versus control peptide.T
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into the corresponding positions of the  LI domain in the
context of intact  L 2. As demonstrated in Figs. 6 and 7, this
manipulation imparted GP Ib  binding capacity to the chi-
meric molecule. Thus, the role of amino acids within the
 M(P201–K217) sequence in GP Ib  binding, which initially
was inferred from the loss in function experiments, was veri-
fied by the gain in function approach. Taken together, the
four approaches substantiated independently the role of
 M(P201–K217) in GP Ib  binding and provided evidence that
two to three critical residues participate in ligand docking.
To date, several lines of evidence have emphasized that
multiple ligands share overlapping binding sites within
 M 2, including the fact that one ligand (e.g., NIF) is capa-
ble of blocking the interaction of multiple ligands (C3bi,
ICAM-1, fibrinogen) with the receptor (15, 45). However,
although the binding sites for these ligands might be over-
lapping, they need not be identical (16, 17). Ustinov and
Plow (22) have proposed a mosaic model in which many of
the same loops and helices of the  MI domain, on or near
its MIDAS face, may engage ligands, but different amino
acid residues within these structures may contact the
ligands. Direct support for this mosaic model is seen within
the K245–R261 segment of the  MI domain, which has been
implicated in both NIF and fibrinogen recognition (23).
Key contact amino acids in this loop for fibrinogen binding
are F246, D254, and P257, whereas Y252 and E258 are involved
in NIF binding. This same  MI domain segment is also in-
volved in C3bi recognition by  M 2 (17).
Under the experimental conditions used in this study,
which assayed the adhesion of activated neutrophils to sur-
face-adherent platelets after vigorous washing, the predom-
inant interaction between neutrophils and platelets ap-
peared to be mediated by  M 2 binding to sGP Ib , based
on the ability of M2 to inhibit  80% of neutrophil adhe-
sion. The enhanced potency of M2 with respect to inhibit-
ing neutrophil adhesion to platelets (IC50   30 nM) com-
pared with BIAcore (kD   17  M) is possibly secondary
to the fact that leukocytes express  M 2 and platelets ex-
press GP Ib  in their native conformations. In contrast, BIA-
core experiments used sGPIb  with immobilized M2 pep-
tide.
Our data do not rule out the possibility of additional
platelet surface receptors for  M 2. Other potential  M 2
ligands present on the platelet membrane include fibrino-
gen (bound to GP IIb-IIIa; 34, 35), ICAM-2 (46), high
molecular weight kininogen (38), and JAM-3 (43). How-
ever, a leukocyte–platelet interaction mediated by fibrino-
gen bridging between  M 2 and GP IIb/IIIa has been dis-
counted by Ostrovsky et al. (47), who found that neither
RGDS peptides nor the replacement of normal platelets
with thrombasthenic platelets (i.e., lacking GP IIb/IIIa) af-
fected the accumulation of the leukocytes on platelets. Al-
though  M 2 binds ICAM-1, this receptor is not found on
platelets. Platelets express a related receptor, ICAM-2 (48),
but Diacovo et al. (5) have shown that ICAM-2 blockade
has no effect on the firm adhesion of neutrophils on mono-
layers of activated platelets under flow. Santoso et al. (43)
have reported recently that  M 2 may also bind to platelet
JAM-3, cooperating with GP Ib  to mediate neutrophil–
platelet adhesive contacts (43).
The present observations also suggest a possible target for
therapeutic intervention. In particular, the specificity of
M2 inhibitory action toward GP Ib  (i.e., noninhibitory
toward fibrinogen) suggests that it might be possible to pre-
vent leukocyte attachment to platelets by targeting GP Ib 
without inhibiting other  M 2 functions. Our recent obser-
vations have identified  M 2 as a molecular determinant of
neointimal thickening after experimental arterial injury that
produces endothelial denudation and platelet deposition.
We found that antibody-mediated blockade (49) or selec-
tive absence (50) of  M 2 impaired transplatelet leukocyte
migration into the vessel wall, diminishing medial leuko-
cyte accumulation and neointimal thickening after experi-
mental angioplasty or endovascular stent implantation.
Therefore, this study identifying the precise binding site re-
sponsible for  M 2–GP Ib  interaction might provide a
molecular strategy for disrupting leukocyte–platelet com-
plexes that promote vascular inflammation in thrombosis,
atherosclerosis, and angioplasty-related restenosis.
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Glycosylation restores survival of chilled blood platelets. Science. 301:
1531–1534.) have recently reported that chilled platelets are cleared by
hepatic macrophage  M 2 receptors via an interaction between platelet
GP I   and a non–I-domain, lectin-binding site within aM 2.
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